Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It targets specific cancers such as chronic myeloid leukemia and gastrointestinal stromal tumor, acting in adult patients who require targeted therapy.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required, and regulatory support.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine kinase pathways, providing targeted therapy for several cancers. - Chronic myeloid leukemia (CML): reduces disease progression and improves survival by inhibiting BCR‑ABL kinase activity. - Gastrointestinal stromal tumor (GIST): limits tumor growth through c‑KIT inhibition. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by blocking BCR‑ABL driven proliferation.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Edema - Muscle cramps or pain - Fatigue - Diarrhea

Serious or Rare Side Effects: - Neutropenia or severe leukopenia - Hepatotoxicity (elevated liver enzymes, hepatitis) - Cardiac failure or reduced left‑ventricular function - Severe hemorrhage or gastrointestinal perforation

When prescribing Imatinib, clinicians should observe several safety measures to minimize risk. - Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia. - Assess liver function: check hepatic enzymes before initiation and periodically during therapy. - Evaluate cardiac status: perform baseline and periodic echocardiograms in patients with cardiac risk factors. - Avoid use in severe infections: postpone treatment until infection is controlled. - Use caution in pregnancy: discuss potential risks with women of child‑bearing potential; consider alternative therapy. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Imatinib interacts with several medicines; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels and toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower imatinib concentrations, reducing effectiveness. - Antacids containing aluminum or magnesium hydroxide: can impair absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., midazolam, cyclosporine): may require dose adjustment. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmias. - Warfarin: may enhance anticoagulant effect; monitor INR closely.